Rigel Pharmaceuticals Inc (RIGL)
Quote as of 10:20 AM ET 07/29/2010 (NASDAQ GM)
| Last: 8.09 |
Change: ($0.01) |
Percent Change: -0.12 |
Volume: 16,325 |
Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Latest News
7:30:00 AM 7/28/2010
Rigel to Present at BMO Capital Markets Healthcare Conference
SOUTH SAN FRANCISCO, Calif., July 28, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York City on Thursday, August 5th at 2:15 p.m. EDT.
7:30:00 AM 6/3/2010
Rigel Announces Presentation at Three Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 3, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows:
7:30:00 AM 6/1/2010
Rigel Pharmaceuticals Names Raul Rodriguez President
SOUTH SAN FRANCISCO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (RIGL) today announced the promotion of three members of senior management, effective immediately. Raul R. Rodriguez has been named president in addition to his position of chief operating officer; Dolly Vance assumes the title general counsel and executive vice president of Corporate Affairs; and Ryan Maynard is executive vice president and chief financial officer. Each of them has been a member of the Rigel team for approximately 10 years, and has served as a member of senior management throughout the company's clinical growth stage.
7:30:00 AM 4/30/2010
Rigel Receives Innovators Award of Excellence in Life Sciences
SOUTH SAN FRANCISCO, Calif., April 30, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (RIGL) has been named one of the recipients of the 2010 Innovators Award of Excellence by the San Mateo County Economic Development Association (SAMCEDA). The award will be presented at the association's Innovators luncheon today at the Oracle Conference Center in Redwood City. Donald G. Payan, Rigel's co-founder, executive vice president and president of Discovery and Research will accept the award on Rigel's behalf.